A Phase 1 Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer

Investigators performed a Phase I dose-escalation study of pembrolizumab and the angiopoietin 1/2 inhibitor trebananib. This multicenter trial enrolled patients with metastatic ovarian cancer or microsatellite stable colorectal cancer.